ClinicalTrials.gg
CompletedNCT03842163TTRACKUpdated Feb 12, 2024Results posted

Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology

An observational study in Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), sponsored by Pfizer. Completed at 18 sites in 10 countries. Open to participants aged 50 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-02-12.

Sponsored by Pfizer · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
812
Ages
50 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Cardiomyopathy, Hypertrophic with a site in France — 9 open to participants now, 12 under way, 5 of them phase 3. Cardiomyopathy, Hypertrophic · France.

Enrollment
4th of 12
812 · median 297
Started
2018
with 2 others
Observational
12 of 33
5 open now
Registered
16th of 33
by date

Among the 33 studies in Cardiomyopathy, Hypertrophic with a site in France, this one is the 4th largest by enrollment of the 12 observational ones that give a count, is one of 3 that started in 2018, is one of 12 observational ones, and was the 16th registered.

Cardiomyopathy, Hypertrophic

364 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 117 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

9 of the 33 studies in Cardiomyopathy, Hypertrophic with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 50 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Cardiomyopathy, Hypertrophic with a site in France, or all of them as a file.
02

Study summary

The main purpose of this study is to determine the prevalence of ATTR Cardiomyopathy among patients admitted due to Left Ventricular Hypertrophy (LVH) >15mm of unknown etiology by using a 99mTc-tracer scintigraphy based protocol

03

Conditions studied

  • Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Keywords

  • Scintigraphy
  • Gammagraphy
  • TTR
  • ATTR
  • Hypertrophic cardiomyopathy (HCM)
  • HCM
04

Who can participate

Ages eligible
50 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with HCM from undiagnosed etiology

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient signed inform consent.
  • Males and Females.
  • Age ≥50 years.
  • Left ventricular hypertrophy (LVH) defined as end-diastolic LV maximum wall thickness (MWT) ≥15mm in Echocardiogram.
  • Plan to undergo or recently underwent radionuclide bone scintigraphy and/or SPECT with any of the following radio labelled tracers: 99mTc-DPD or 99mTc-PYP or 99mTc-HMDP.

Exclusion criteria

Exclusion criteria:

  • Etiological diagnosis explaining the LVH (p.e. Sarcomeric HCM, Myeloma, Fabry disease, Sarcoidosis, Any type of amyloidosis (AA, AL, TTR)
  • Severe aortic stenosis defined as aortic valve area (AVA) \< 1.0 cm2
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
812 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with LVH of unknown etiology

    Diagnostic Test: Diagnosis of TTR amyloidosis cardiomyopathy

Interventions

  • Diagnostic testDiagnosis of TTR amyloidosis cardiomyopathy

    Diagnosis of TTR amyloidosis cardiomyopathy with scintigraphy

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Cardiac Fixation at the Radionuclide Bone Scintigraphy and/or Single Photon Emission Computed Tomography (SPECT): FAS1

    Percentage of participants with cardiac fixation on a radionuclide bone scintigraphy and/or SPECT performed with 99mTc-DPD or 99mTc-PYP or 999mTc-HMDP among participants with LVH from an undiagnosed etiology were reported in this outcome measure. Scintigraphy was defined at each bone site according to the standard grading: Grade 0 = absent cardiac uptake, Grade 1=mild uptake less than bone, Grade 2=moderate uptake equal to bone and Grade 3=high uptake greater than bone.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

Secondary outcomes

  1. Percentage of Participants With Transthyretin Amyloid (ATTR): FAS 1

    Transthyretin amyloidosis is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  2. Percentage of Participants With ATTR or With Suspicion of Monoclonal Gammopathy of Undetermined Significance (MGUS) / Light Chain Amyloidosis (AL): FAS 1

    Transthyretin amyloidosis is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  3. Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): Full Analysis Set 2 (FAS 2)

    Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  4. Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): Full Analysis Set 3 (FAS 3)

    Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  5. Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): FAS 3.1

    Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  6. Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): FAS 3.2

    Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  7. Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 2

    Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  8. Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3

    Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  9. Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3.1

    Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  10. Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3.2

    Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  11. Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 2

    Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants with TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  12. Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3

    Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants with TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  13. Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3.1

    Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants with TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  14. Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3.2

    Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants With TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  15. Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 1

    Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a left ventricular (LV) wall thickness greater than or equal to (\>=) 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  16. Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 2

    Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  17. Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3

    Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  18. Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3.1

    Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  19. Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3.2

    Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  20. Percentage of Participants With Senso-Motor Polyneuropathy: FAS 2

    Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags Electronic Case Report Form (e-CRF) part was considered as participants with a senso-motor polyneuropathy.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  21. Percentage of Participants With Senso-Motor Polyneuropathy: FAS 3

    Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags e-CRF part was considered as participants with a senso-motor polyneuropathy.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  22. Percentage of Participants With Senso-Motor Polyneuropathy: FAS 3.1

    Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags e-CRF part was considered as participants with a senso-motor polyneuropathy.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  23. Percentage of Participants With Senso-Motor Polyneuropathy: FAS 3.2

    Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags e-CRF part was considered as participants with a senso-motor polyneuropathy.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  24. Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 2

    CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  25. Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3

    CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  26. Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3.1

    CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  27. Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3.2

    CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  28. Percentage of Participants With Autonomic Dysfunction: FAS 2

    Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  29. Percentage of Participants With Autonomic Dysfunction: FAS 3

    Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  30. Percentage of Participants With Autonomic Dysfunction: FAS 3.1

    Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  31. Percentage of Participants With Autonomic Dysfunction: FAS 3.2

    Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  32. Percentage of Participants With Cardiological Manifestations: FAS 2

    Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval less than (\<) 80 milliseconds (ms) or greater than (\>) 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  33. Percentage of Participants With Cardiological Manifestations: FAS 3

    Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval \< 80 ms or \> 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  34. Percentage of Participants With Cardiological Manifestations: FAS 3.1

    Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval \< 80 ms or \> 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  35. Percentage of Participants With Cardiological Manifestations: FAS 3.2

    Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval \< 80 ms or \> 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  36. Percentage of Participants With Laboratory Abnormalities: FAS 2

    Laboratory parameters that were considered as out of range included creatinine \<45 micromole per liter (μmol/L) or greater than 104 μmol/L w; haemoglobin, participants with a value lower than 11.5 grams per deciliter (g/dL) or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 picograms per milliliter (pg/mL); N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  37. Percentage of Participants With Laboratory Abnormalities: FAS 3

    Laboratory parameters that were considered as out of range included creatinine \<45 μmol/L or greater than 104 μmol/L w; haemoglobin value lower than 11.5 g/dL or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 pg/mL; N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  38. Percentage of Participants With Laboratory Abnormalities: FAS 3.1

    Laboratory parameters that were considered as out of range included creatinine \<45 μmol/L or greater than 104 μmol/L w; haemoglobin value lower than 11.5 g/dL or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 pg/mL; N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  39. Percentage of Participants With Laboratory Abnormalities: FAS 3.2

    Laboratory parameters that were considered as out of range included creatinine \<45 μmol/L or greater than 104 μmol/L w; haemoglobin value lower than 11.5 g/dL or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 pg/mL; N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  40. Number of Participants According to Presence of Neurological Red Flag: FAS1

    Participants were classified according to presence of neurological red flag as 'Yes' or 'No'.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  41. Number of Participants According to Presence of Neurological Red Flag: FAS 2

    Participants were classified according to presence of neurological red flag as 'Yes' or 'No'.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  42. Number of Participants According to Discrepancies Between Scintigraphy Result and Single Photon Emission Computed Tomography (SPECT) Result: FAS1

    Grade of scintigraphy evaluated by the investigator and Grade of SPECT: Grade 0 = absent cardiac uptake, Grade 1=mild uptake less than bone, Grade 2=moderate uptake equal to bone and Grade 3=high uptake greater than bone. Only categories with non-zero values were reported.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  43. Cardiological Assessments - Blood Pressure: FAS 2

    Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were evaluated.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  44. Cardiological Assessments - Blood Pressure: FAS 3

    SBP and DBP were evaluated.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  45. Cardiological Assessments - Blood Pressure: FAS 3.1

    SBP and DBP were evaluated.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  46. Cardiological Assessments - Blood Pressure: FAS 3.2

    SBP and DBP were evaluated.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  47. Number of Participants According to History of Clinical Parameters at Baseline: FAS 2

    Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.

    Time frame: Baseline

  48. Number of Participants According to History of Clinical Parameters at Baseline: FAS 3

    Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.

    Time frame: Baseline

  49. Number of Participants According to History of Clinical Parameters at Baseline: FAS 3.1

    Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.

    Time frame: Baseline

  50. Number of Participants According to History of Clinical Parameters at Baseline: FAS 3.2

    Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.

    Time frame: Baseline

  51. Number of Participants Classified According to New York Heart Association (NYHA) Class: FAS 2

    Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  52. Number of Participants Classified According to New York Heart Association (NYHA) Class: FAS 3

    Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  53. Number of Participants Classified According to New York Heart Association (NYHA) Class: FAS 3.1

    Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  54. Number of Participants Classified According to New York Heart Association (NYHA) Class: FAS 3.2

    Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  55. Number of Participants With Atrial Fibrillation Assessment: FAS 2

    Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  56. Number of Participants With Atrial Fibrillation Assessment: FAS 3

    Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  57. Number of Participants With Atrial Fibrillation Assessment: FAS 3.1

    Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  58. Number of Participants With Atrial Fibrillation Assessment: FAS 3.2

    Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  59. Number of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 2

    Participants who used pacemaker and ICD were reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  60. Number of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 3

    Participants who used pacemaker and ICD were reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  61. Number of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 3.1

    Participants who used pacemaker and ICD were reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  62. Number of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 3.2

    Participants who used pacemaker and ICD were reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  63. Number of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 2

    Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  64. Number of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 3

    Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  65. Number of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 3.1

    Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  66. Number of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 3.2

    Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  67. Number of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 2

    Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  68. Number of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 3

    Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  69. Number of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 3.1

    Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  70. Number of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 3.2

    Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  71. Heart Rate Parameter for Participants Without Paced: FAS 2

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  72. Heart Rate Parameter for Participants Without Paced: FAS 3

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  73. Heart Rate Parameter for Participants Without Paced: FAS 3.1

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  74. Heart Rate Parameter for Participants Without Paced: FAS 3.2

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  75. Number of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 2

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  76. Number of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 3

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  77. Number of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 3.1

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  78. Number of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 3.2

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  79. Sokolow Index: FAS 2

    Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  80. Sokolow Index: FAS 3

    Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  81. Sokolow Index: FAS 3.1

    Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  82. Sokolow Index: FAS 3.2

    Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  83. Left Ventricular Ejection Fraction (LVEF): FAS 2

    LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  84. Left Ventricular Ejection Fraction (LVEF): FAS 3

    LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  85. Left Ventricular Ejection Fraction (LVEF): FAS 3.1

    LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  86. Left Ventricular Ejection Fraction (LVEF): FAS 3.2

    LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  87. Number of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 2

    LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  88. Number of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 3

    LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  89. Number of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 3.1

    LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  90. Number of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 3.2

    LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  91. Number of Participants Categorized According to Perseverance of Strain Apical: FAS 2

    Participants were classified according to strain apical preserved as 'No' and 'Yes'.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  92. Number of Participants Categorized According to Perseverance of Strain Apical: FAS 3

    Participants were classified according to strain apical preserved as 'No' and 'Yes'.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  93. Number of Participants Categorized According to Perseverance of Strain Apical: FAS 3.1

    Participants were classified according to strain apical preserved as 'No' and 'Yes'.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  94. Number of Participants Categorized According to Perseverance of Strain Apical: FAS 3.2

    Participants were classified according to strain apical preserved as 'No' and 'Yes'.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  95. LV End Diastolic Diameter: FAS 2

    Left ventricular end-diastolic diameter (LVEDD) reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  96. LV End Diastolic Diameter: FAS 3

    LVEDD reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  97. LV End Diastolic Diameter: FAS 3.1

    LVEDD reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  98. LV End Diastolic Diameter: FAS 3.2

    LVEDD reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  99. Maximum Wall Thickness: FAS 2

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  100. Maximum Wall Thickness: FAS 3

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  101. Maximum Wall Thickness: FAS 3.1

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  102. Maximum Wall Thickness: FAS 3.2

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  103. Number of Participants According to Type of Hypertrophic Pattern: FAS 2

    Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  104. Number of Participants According to Type of Hypertrophic Pattern: FAS 3

    Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  105. Number of Participants According to Type of Hypertrophic Pattern: FAS 3.1

    Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  106. Number of Participants According to Type of Hypertrophic Pattern: FAS 3.2

    Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  107. LV Mass Index (LVMI): FAS 2

    Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  108. LV Mass Index (LVMI): FAS 3

    Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  109. LV Mass Index (LVMI): FAS 3.1

    Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  110. LV Mass Index (LVMI): FAS 3.2

    Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  111. Aortic Valvular Stenosis - Aortic Valve Area: FAS 2

    Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  112. Aortic Valvular Stenosis - Aortic Valve Area: FAS 3

    Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  113. Aortic Valvular Stenosis - Aortic Valve Area: FAS 3.1

    Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

  114. Aortic Valvular Stenosis - Aortic Valve Area: FAS 3.2

    Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.

    Time frame: During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)

07

Results

Posted Feb 12, 2024

Participant flow

Data of participants diagnosed with left ventricular hypertrophy (LVH) confirmed by bone scintigraphy and/or single photon emission computed tomography (SPECT) and greater than or equal to (\>=) 50 years of age were observed in this study.

Participant flow — Overall Study
MilestoneAll Participants
Started812
Full analysis set 1766
Full analysis set 2 (subset of fas 1)245
Full analysis set 3 (subset of fas 2)208
Full analysis set 3.1137
Full analysis set 3.256
Completed766
Not completed46
Withdrew: Did not meet inclusion criteria (age less than 50 years)2
Withdrew: Scintigraphy was not performed44

Outcome measures

PrimaryPercentage of Participants With Cardiac Fixation at the Radionuclide Bone Scintigraphy and/or Single Photon Emission Computed Tomography (SPECT): FAS1

Percentage of participants with cardiac fixation on a radionuclide bone scintigraphy and/or SPECT performed with 99mTc-DPD or 99mTc-PYP or 999mTc-HMDP among participants with LVH from an undiagnosed etiology were reported in this outcome measure. Scintigraphy was defined at each bone site according to the standard grading: Grade 0 = absent cardiac uptake, Grade 1=mild uptake less than bone, Grade 2=moderate uptake equal to bone and Grade 3=high uptake greater than bone.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Cardiac Fixation at the Radionuclide Bone Scintigraphy and/or Single Photon Emission Computed Tomography (SPECT): FAS1
Percentage of participantsAll Participants
Percentage of Participants With Cardiac Fixation at the Radionuclide Bone Scintigraphy and/or Single Photon Emission Computed Tomography (SPECT): FAS132.0 (28.8 to 35.4)
SecondaryPercentage of Participants With Transthyretin Amyloid (ATTR): FAS 1

Transthyretin amyloidosis is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Transthyretin Amyloid (ATTR): FAS 1
Percentage of participantsAll Participants
Percentage of Participants With Transthyretin Amyloid (ATTR): FAS 117.9 (15.3 to 20.8)
SecondaryPercentage of Participants With ATTR or With Suspicion of Monoclonal Gammopathy of Undetermined Significance (MGUS) / Light Chain Amyloidosis (AL): FAS 1

Transthyretin amyloidosis is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With ATTR or With Suspicion of Monoclonal Gammopathy of Undetermined Significance (MGUS) / Light Chain Amyloidosis (AL): FAS 1
Percentage of participantsAll Participants
Percentage of Participants With ATTR or With Suspicion of Monoclonal Gammopathy of Undetermined Significance (MGUS) / Light Chain Amyloidosis (AL): FAS 125.2 (22.3 to 28.4)
SecondaryPercentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): Full Analysis Set 2 (FAS 2)

Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): Full Analysis Set 2 (FAS 2)
Percentage of participantsAll Participants
Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): Full Analysis Set 2 (FAS 2)6.5 (3.8 to 10.8)
SecondaryPercentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): Full Analysis Set 3 (FAS 3)

Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): Full Analysis Set 3 (FAS 3)
Percentage of participantsAll Participants
Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): Full Analysis Set 3 (FAS 3)6.9 (4.1 to 11.5)
SecondaryPercentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): FAS 3.1

Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): FAS 3.1
Percentage of participantsAll Participants
Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): FAS 3.18.7 (4.9 to 14.8)
SecondaryPercentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): FAS 3.2

Percentage of participants with hereditary ATTRv were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with variant transthyretin was considered as ATTRv.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): FAS 3.2
Percentage of participantsAll Participants
Percentage of Participants With Hereditary Transthyretin Amyloid (ATTRv): FAS 3.23.7 (1.0 to 12.5)
SecondaryPercentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 2

Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 2
Percentage of participantsAll Participants
Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 293.5 (89.2 to 96.2)
SecondaryPercentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3

Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3
Percentage of participantsAll Participants
Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 393.1 (88.5 to 95.9)
SecondaryPercentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3.1

Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3.1
Percentage of participantsAll Participants
Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3.191.3 (85.2 to 95.1)
SecondaryPercentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3.2

Percentage of participants with ATTRwt were reported in this outcome measure. ATTR participants with a ATTR gene sequencing with a result of 'no mutation' was considered as ATTRwt.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3.2
Percentage of participantsAll Participants
Percentage of Participants With Wild Type Transthyretin Amyloid (ATTRwt): FAS 3.296.3 (87.5 to 99.0)
SecondaryNumber of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 2

Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants with TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 2
ParticipantsAll Participants
Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 213
SecondaryNumber of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3

Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants with TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3
ParticipantsAll Participants
Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 313
SecondaryNumber of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3.1

Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants with TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3.1
ParticipantsAll Participants
Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3.111
SecondaryNumber of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3.2

Scintigraphy is the procedure used to diagnose, stage, and monitor disease. A small amount of a radioactive chemical (radionuclide) was injected into a vein or swallowed. Number of participants With TTR genetic mutations among those who had positive scintigraphy were reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3.2
ParticipantsAll Participants
Number of Participants With Transthyretin (TTR) Genetic Mutations Among Those Who Had Positive Scintigraphy: FAS 3.22
SecondaryPercentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 1

Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a left ventricular (LV) wall thickness greater than or equal to (\>=) 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 1
Percentage of participantsAll Participants
Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 117.1 (14.6 to 19.9)
SecondaryPercentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 2

Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 2
Percentage of participantsAll Participants
Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 211.8 (8.4 to 16.5)
SecondaryPercentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3

Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3
Percentage of participantsAll Participants
Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 39.6 (6.3 to 14.4)
SecondaryPercentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3.1

Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3.1
Percentage of participantsAll Participants
Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3.110.9 (6.7 to 17.3)
SecondaryPercentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3.2

Percentage of participants with any of the familial history of known CM, PN or SCD among their relatives were reported in this outcome measure. Family history for each disease was considered for 1st degree parent, siblings, and 2nd/3rd grade family. CM was defined by the presence of a LV wall thickness \>= 15 mm in one or more LV myocardial segments that is not explained solely by abnormal loading conditions. Polyneuropathy was defined as the simultaneous malfunction of many peripheral nerves throughout the body. SCD was defined as death due to a cardiovascular cause that occurs within one hour of the onset of symptoms. A sudden cardiac arrest occurs when the heart stops beating or is not beating sufficiently to maintain perfusion and life.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3.2
Percentage of participantsAll Participants
Percentage of Participants With Any Familial History of Known Cardiomyopathy (CM), Polyneuropathy (PN) or Sudden Cardiac Death (SCD) Among Their Relatives (Parents, Siblings and 2nd /3rd Grade Family): FAS 3.27.1 (2.8 to 17.0)
SecondaryPercentage of Participants With Senso-Motor Polyneuropathy: FAS 2

Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags Electronic Case Report Form (e-CRF) part was considered as participants with a senso-motor polyneuropathy.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Senso-Motor Polyneuropathy: FAS 2
Percentage of participantsAll Participants
Percentage of Participants With Senso-Motor Polyneuropathy: FAS 280.0 (74.5 to 84.5)
SecondaryPercentage of Participants With Senso-Motor Polyneuropathy: FAS 3

Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags e-CRF part was considered as participants with a senso-motor polyneuropathy.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Senso-Motor Polyneuropathy: FAS 3
Percentage of participantsAll Participants
Percentage of Participants With Senso-Motor Polyneuropathy: FAS 386.1 (80.7 to 90.1)
SecondaryPercentage of Participants With Senso-Motor Polyneuropathy: FAS 3.1

Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags e-CRF part was considered as participants with a senso-motor polyneuropathy.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Senso-Motor Polyneuropathy: FAS 3.1
Percentage of participantsAll Participants
Percentage of Participants With Senso-Motor Polyneuropathy: FAS 3.189.8 (83.6 to 93.8)
SecondaryPercentage of Participants With Senso-Motor Polyneuropathy: FAS 3.2

Participants with at least one red flag in the neurological part of the ATTR-Amyloidosis red flags e-CRF part was considered as participants with a senso-motor polyneuropathy.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Senso-Motor Polyneuropathy: FAS 3.2
Percentage of participantsAll Participants
Percentage of Participants With Senso-Motor Polyneuropathy: FAS 3.285.7 (74.3 to 92.6)
SecondaryPercentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 2

CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 2
Percentage of participantsAll Participants
Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 248.6 (42.4 to 54.8)
SecondaryPercentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3

CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3
Percentage of participantsAll Participants
Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 354.8 (48.0 to 61.4)
SecondaryPercentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3.1

CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3.1
Percentage of participantsAll Participants
Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3.160.6 (52.2 to 68.4)
SecondaryPercentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3.2

CTS was defined as a common neurological disorder that occurs when the median nerve, which runs from your forearm into the palm of the hand, becomes pressed or squeezed at the wrist. Participants with a CTS were participants with a bilateral or unilateral CTS.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3.2
Percentage of participantsAll Participants
Percentage of Participants With Carpal Tunnel Syndrome (CTS): FAS 3.248.2 (35.7 to 61.0)
SecondaryPercentage of Participants With Autonomic Dysfunction: FAS 2

Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Autonomic Dysfunction: FAS 2
Percentage of participantsAll Participants
Percentage of Participants With Autonomic Dysfunction: FAS 255.9 (49.7 to 62.0)
SecondaryPercentage of Participants With Autonomic Dysfunction: FAS 3

Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Autonomic Dysfunction: FAS 3
Percentage of participantsAll Participants
Percentage of Participants With Autonomic Dysfunction: FAS 358.7 (51.9 to 65.1)
SecondaryPercentage of Participants With Autonomic Dysfunction: FAS 3.1

Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Autonomic Dysfunction: FAS 3.1
Percentage of participantsAll Participants
Percentage of Participants With Autonomic Dysfunction: FAS 3.161.3 (53.0 to 69.1)
SecondaryPercentage of Participants With Autonomic Dysfunction: FAS 3.2

Participants with autonomic dysfunction were participants with at least one autonomic sign or autonomic symptom = "Yes".

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Autonomic Dysfunction: FAS 3.2
Percentage of participantsAll Participants
Percentage of Participants With Autonomic Dysfunction: FAS 3.257.1 (44.1 to 69.2)
SecondaryPercentage of Participants With Cardiological Manifestations: FAS 2

Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval less than (\<) 80 milliseconds (ms) or greater than (\>) 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Cardiological Manifestations: FAS 2
Percentage of participantsAll Participants
Percentage of Participants With Cardiological Manifestations: FAS 298.0 (95.3 to 99.1)
SecondaryPercentage of Participants With Cardiological Manifestations: FAS 3

Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval \< 80 ms or \> 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Cardiological Manifestations: FAS 3
Percentage of participantsAll Participants
Percentage of Participants With Cardiological Manifestations: FAS 398.1 (95.2 to 99.2)
SecondaryPercentage of Participants With Cardiological Manifestations: FAS 3.1

Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval \< 80 ms or \> 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Cardiological Manifestations: FAS 3.1
Percentage of participantsAll Participants
Percentage of Participants With Cardiological Manifestations: FAS 3.197.8 (93.8 to 99.3)
SecondaryPercentage of Participants With Cardiological Manifestations: FAS 3.2

Participants with cardiological manifestations was defined as participants with at least one of the following criteria fulfilled from data collected from e-CRF: cardiological assessments: atrial fibrillation (yes permanent), pacemaker (yes), AICD (yes); in magnetic resonance imaging (MRI) part: LGE (positive); electrocardiogram (ECG) part: PR interval \< 80 ms or \> 350 ms QRS interval \< 60 ms or \> 250 ms, Sokolow index \< 1 mm or \> 70 mm, pseudo MI pattern (yes), PPOr precordial R wave progression(yes), LBBB, RBBB, paced and intraventricular conduct delay (ticked), LVOT (yes), if longitudinal strain is done, strain apical preserved (yes), LV end-diastolic diameter \<20 mm or \>80 mm, MWT \<15 mm or \>100 mm, MWT at septum \<3 mm or \>50 mm, MWT posterior wall \<3 mm or \>50 mm, LV mass index \<40 g/m\^2 or \>160 g/m\^2, Maximal aortic velocity \>5 m/s, Mean gradient of Aortic valvular stenosis \>70 mmHg, Area of Aortic valvular stenosis \<0.2 cm\^2 or \>3 cm\^2.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Cardiological Manifestations: FAS 3.2
Percentage of participantsAll Participants
Percentage of Participants With Cardiological Manifestations: FAS 3.298.2 (90.6 to 99.7)
SecondaryPercentage of Participants With Laboratory Abnormalities: FAS 2

Laboratory parameters that were considered as out of range included creatinine \<45 micromole per liter (μmol/L) or greater than 104 μmol/L w; haemoglobin, participants with a value lower than 11.5 grams per deciliter (g/dL) or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 picograms per milliliter (pg/mL); N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Laboratory Abnormalities: FAS 2
Percentage of participantsAll Participants
Creatinine out of range37.6 (31.7 to 43.8)
Haemoglobin out of range30.2 (24.8 to 36.2)
BNP out of range62.9 (56.7 to 68.7)
NTproBNP out of range81.2 (75.9 to 85.6)
Troponin I out of range3.7 (1.9 to 6.8)
SecondaryPercentage of Participants With Laboratory Abnormalities: FAS 3

Laboratory parameters that were considered as out of range included creatinine \<45 μmol/L or greater than 104 μmol/L w; haemoglobin value lower than 11.5 g/dL or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 pg/mL; N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Laboratory Abnormalities: FAS 3
Percentage of participantsAll Participants
Creatinine out of range42.3 (35.8 to 49.1)
Haemoglobin out of range33.2 (27.1 to 39.8)
BNP out of range69.7 (63.2 to 75.6)
NTproBNP out of range88.9 (84.0 to 92.5)
Troponin I out of range3.8 (2.0 to 7.4)
SecondaryPercentage of Participants With Laboratory Abnormalities: FAS 3.1

Laboratory parameters that were considered as out of range included creatinine \<45 μmol/L or greater than 104 μmol/L w; haemoglobin value lower than 11.5 g/dL or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 pg/mL; N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Laboratory Abnormalities: FAS 3.1
Percentage of participantsAll Participants
Creatinine out of range34.3 (26.9 to 42.6)
Haemoglobin out of range34.3 (26.9 to 42.6)
BNP out of range68.6 (60.4 to 75.8)
NTproBNP out of range90.5 (84.4 to 94.4)
Troponin I out of range4.4 (2.0 to 9.2)
SecondaryPercentage of Participants With Laboratory Abnormalities: FAS 3.2

Laboratory parameters that were considered as out of range included creatinine \<45 μmol/L or greater than 104 μmol/L w; haemoglobin value lower than 11.5 g/dL or higher than 16 g/dL was considered as out of range; Brain natriuretic peptide (BNP) value higher than 100 pg/mL; N-terminal pro-brain natriuretic peptide (NTproBNP), value higher than 125 pg/mL; Troponin I value higher than 26 pg/mL.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Laboratory Abnormalities: FAS 3.2
Percentage of participantsAll Participants
Creatinine out of range58.9 (45.9 to 70.8)
Haemoglobin out of range35.7 (24.5 to 48.8)
BNP out of range89.3 (78.5 to 95.0)
NTproBNP out of range98.2 (90.6 to 99.7)
Troponin I out of range1.8 (0.3 to 9.4)
SecondaryNumber of Participants According to Presence of Neurological Red Flag: FAS1

Participants were classified according to presence of neurological red flag as 'Yes' or 'No'.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants According to Presence of Neurological Red Flag: FAS1
ParticipantsAll Participants
Yes143
No623
SecondaryNumber of Participants According to Presence of Neurological Red Flag: FAS 2

Participants were classified according to presence of neurological red flag as 'Yes' or 'No'.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants According to Presence of Neurological Red Flag: FAS 2
ParticipantsAll Participants
Yes142
No103
SecondaryNumber of Participants According to Discrepancies Between Scintigraphy Result and Single Photon Emission Computed Tomography (SPECT) Result: FAS1

Grade of scintigraphy evaluated by the investigator and Grade of SPECT: Grade 0 = absent cardiac uptake, Grade 1=mild uptake less than bone, Grade 2=moderate uptake equal to bone and Grade 3=high uptake greater than bone. Only categories with non-zero values were reported.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants According to Discrepancies Between Scintigraphy Result and Single Photon Emission Computed Tomography (SPECT) Result: FAS1
ParticipantsAll Participants
Investigator: Grade 0; SPECT: Grade 043
Investigator: Grade 0; SPECT: Grade 13
Investigator: Grade 1; SPECT: Grade 15
Investigator: Grade 2; SPECT: Grade 216
Investigator: Grade 3; SPECT: Grade 38
SecondaryCardiological Assessments - Blood Pressure: FAS 2

Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were evaluated.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · mmHg
Cardiological Assessments - Blood Pressure: FAS 2
mmHgAll Participants
DBP75.6 ± 12.4
SBP132.5 ± 20.0
SecondaryCardiological Assessments - Blood Pressure: FAS 3

SBP and DBP were evaluated.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · mmHg
Cardiological Assessments - Blood Pressure: FAS 3
mmHgAll Participants
DBP74.6 ± 12.0
SBP131.0 ± 19.0
SecondaryCardiological Assessments - Blood Pressure: FAS 3.1

SBP and DBP were evaluated.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · mmHg
Cardiological Assessments - Blood Pressure: FAS 3.1
mmHgAll Participants
DBP75.6 ± 11.8
SBP130.9 ± 18.1
SecondaryCardiological Assessments - Blood Pressure: FAS 3.2

SBP and DBP were evaluated.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · mmHg
Cardiological Assessments - Blood Pressure: FAS 3.2
mmHgAll Participants
DBP74.2 ± 11.9
SBP131.9 ± 20.5
SecondaryNumber of Participants According to History of Clinical Parameters at Baseline: FAS 2

Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Number of Participants According to History of Clinical Parameters at Baseline: FAS 2
ParticipantsAll Participants
Diagnosed hypertension — No78
Diagnosed hypertension — Yes167
Antihypertensive medication — No89
Antihypertensive medication — Yes156
Coronary artery disease — No184
Coronary artery disease — Yes61
Renal insufficiency — No177
Renal insufficiency — Yes68
Diabetes Mellitus — No193
Diabetes Mellitus — Yes52
Lumbar spinal stenosis — No221
Lumbar spinal stenosis — Yes24
Carpal tunnel syndrome — No164
Carpal tunnel syndrome — Yes81
SecondaryNumber of Participants According to History of Clinical Parameters at Baseline: FAS 3

Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Number of Participants According to History of Clinical Parameters at Baseline: FAS 3
ParticipantsAll Participants
Diagnosed hypertension — No77
Diagnosed hypertension — Yes131
Antihypertensive medication — No88
Antihypertensive medication — Yes120
Coronary artery disease — No162
Coronary artery disease — Yes46
Renal insufficiency — No147
Renal insufficiency — Yes61
Diabetes Mellitus — No175
Diabetes Mellitus — Yes33
Lumbar spinal stenosis — No184
Lumbar spinal stenosis — Yes24
Carpal tunnel syndrome — No130
Carpal tunnel syndrome — Yes78
SecondaryNumber of Participants According to History of Clinical Parameters at Baseline: FAS 3.1

Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Number of Participants According to History of Clinical Parameters at Baseline: FAS 3.1
ParticipantsAll Participants
Diagnosed hypertension — No49
Diagnosed hypertension — Yes88
Antihypertensive medication — No57
Antihypertensive medication — Yes80
Coronary artery disease — No112
Coronary artery disease — Yes25
Renal insufficiency — No102
Renal insufficiency — Yes35
Diabetes Mellitus — No118
Diabetes Mellitus — Yes19
Lumbar spinal stenosis — No121
Lumbar spinal stenosis — Yes16
Carpal tunnel syndrome — No80
Carpal tunnel syndrome — Yes57
SecondaryNumber of Participants According to History of Clinical Parameters at Baseline: FAS 3.2

Clinical parameters' assessment for hypertension, antihypertensive medication, coronary artery disease, renal insufficiency, diabetes mellitus, lumbar spinal stenosis, carpal tunnel syndrome was categorized as 'Yes' and 'No', where Yes indicated presence and No indicated absence.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Number of Participants According to History of Clinical Parameters at Baseline: FAS 3.2
ParticipantsAll Participants
Diagnosed hypertension — No19
Diagnosed hypertension — Yes37
Antihypertensive medication — No22
Antihypertensive medication — Yes34
Coronary artery disease — No43
Coronary artery disease — Yes13
Renal insufficiency — No35
Renal insufficiency — Yes21
Diabetes Mellitus — No45
Diabetes Mellitus — Yes11
Lumbar spinal stenosis — No50
Lumbar spinal stenosis — Yes6
Carpal tunnel syndrome — No37
Carpal tunnel syndrome — Yes19
SecondaryNumber of Participants Classified According to New York Heart Association (NYHA) Class: FAS 2

Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants Classified According to New York Heart Association (NYHA) Class: FAS 2
ParticipantsAll Participants
Class I50
Class II130
Class III57
Class IV7
Missing data1
SecondaryNumber of Participants Classified According to New York Heart Association (NYHA) Class: FAS 3

Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants Classified According to New York Heart Association (NYHA) Class: FAS 3
ParticipantsAll Participants
Class I45
Class II112
Class III45
Class IV5
Missing data1
SecondaryNumber of Participants Classified According to New York Heart Association (NYHA) Class: FAS 3.1

Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants Classified According to New York Heart Association (NYHA) Class: FAS 3.1
ParticipantsAll Participants
Class I34
Class II69
Class III30
Class IV3
Missing data1
SecondaryNumber of Participants Classified According to New York Heart Association (NYHA) Class: FAS 3.2

Participants classified according to NYHA class as Class I, Class II, Class III, Class IV were reported in this outcome measure. Class I: no symptoms and no limitation in ordinary physical activity, such as shortness of breath when walking, climbing stairs. Class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, such as walking short distances (20-100 meters), comfortable only at rest. Class IV: severe limitations and experienced symptoms even while at rest, mostly bedbound participants.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants Classified According to New York Heart Association (NYHA) Class: FAS 3.2
ParticipantsAll Participants
Class I5
Class II38
Class III11
Class IV2
SecondaryNumber of Participants With Atrial Fibrillation Assessment: FAS 2

Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants With Atrial Fibrillation Assessment: FAS 2
ParticipantsAll Participants
No120
Yes permanent90
Yes in the past35
SecondaryNumber of Participants With Atrial Fibrillation Assessment: FAS 3

Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants With Atrial Fibrillation Assessment: FAS 3
ParticipantsAll Participants
No105
Yes permanent78
Yes in the past25
SecondaryNumber of Participants With Atrial Fibrillation Assessment: FAS 3.1

Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants With Atrial Fibrillation Assessment: FAS 3.1
ParticipantsAll Participants
No65
Yes permanent52
Yes in the past20
SecondaryNumber of Participants With Atrial Fibrillation Assessment: FAS 3.2

Participants were classified according to presence of atrial fibrillation as 'No', 'Yes permanent', 'Yes in the past' and were reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants With Atrial Fibrillation Assessment: FAS 3.2
ParticipantsAll Participants
No28
Yes permanent23
Yes in the past5
SecondaryNumber of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 2

Participants who used pacemaker and ICD were reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 2
ParticipantsAll Participants
Pacemaker — Yes30
Pacemaker — No215
ICD — Yes0
ICD — No245
SecondaryNumber of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 3

Participants who used pacemaker and ICD were reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 3
ParticipantsAll Participants
Pacemaker — Yes30
Pacemaker — No178
ICD — Yes0
ICD — No208
SecondaryNumber of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 3.1

Participants who used pacemaker and ICD were reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 3.1
ParticipantsAll Participants
Pacemaker — Yes20
Pacemaker — No117
ICD — Yes0
ICD — No137
SecondaryNumber of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 3.2

Participants who used pacemaker and ICD were reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants With Pacemaker and Implantable Cardiac Defibrillator (ICD): FAS 3.2
ParticipantsAll Participants
Pacemaker — Yes7
Pacemaker — No49
ICD — Yes0
ICD — No56
SecondaryNumber of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 2

Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 2
ParticipantsAll Participants
Negative11
Positive55
SecondaryNumber of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 3

Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 3
ParticipantsAll Participants
Negative7
Positive50
SecondaryNumber of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 3.1

Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 3.1
ParticipantsAll Participants
Negative6
Positive33
SecondaryNumber of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 3.2

Participants with MRI scan performed using LGE classified as 'negative' and 'positive' were reported in this outcome measure. LGE was defined as method where cardiovascular magnetic resonance (CMR) images were obtained after the administration of gadolinium contrast material that accumulated into a tissue with increased extra cellular space.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants With Magnetic Resonance Imaging (MRI) Scan Performed Using Late Gadolinium Enhancement (LGE): FAS 3.2
ParticipantsAll Participants
Negative0
Positive13
SecondaryNumber of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 2

Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 2
ParticipantsAll Participants
No217
Yes18
SecondaryNumber of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 3

Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 3
ParticipantsAll Participants
No182
Yes18
SecondaryNumber of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 3.1

Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 3.1
ParticipantsAll Participants
No122
Yes10
SecondaryNumber of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 3.2

Participants classified according to assessment for ECG for paced participants as 'Yes' or 'No' were reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants According to Assessment for Electrocardiogram (ECG) Paced: FAS 3.2
ParticipantsAll Participants
No49
Yes6
SecondaryHeart Rate Parameter for Participants Without Paced: FAS 2
Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Beats per minute
Heart Rate Parameter for Participants Without Paced: FAS 2
Beats per minuteAll Participants
Heart Rate Parameter for Participants Without Paced: FAS 273.3 ± 15.1
SecondaryHeart Rate Parameter for Participants Without Paced: FAS 3
Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Beats per minute
Heart Rate Parameter for Participants Without Paced: FAS 3
Beats per minuteAll Participants
Heart Rate Parameter for Participants Without Paced: FAS 373.2 ± 14.7
SecondaryHeart Rate Parameter for Participants Without Paced: FAS 3.1
Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Beats per minute
Heart Rate Parameter for Participants Without Paced: FAS 3.1
Beats per minuteAll Participants
Heart Rate Parameter for Participants Without Paced: FAS 3.173.4 ± 15.9
SecondaryHeart Rate Parameter for Participants Without Paced: FAS 3.2
Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Beats per minute
Heart Rate Parameter for Participants Without Paced: FAS 3.2
Beats per minuteAll Participants
Heart Rate Parameter for Participants Without Paced: FAS 3.272.7 ± 12.1
SecondaryNumber of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 2
Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 2
ParticipantsAll Participants
No86
Yes135
Missing6
SecondaryNumber of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 3
Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 3
ParticipantsAll Participants
No72
Yes114
Missing4
SecondaryNumber of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 3.1
Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 3.1
ParticipantsAll Participants
No51
Yes73
Missing3
SecondaryNumber of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 3.2
Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants Assessed for Sinus Rhythm Parameter for Participants Without Paced: FAS 3.2
ParticipantsAll Participants
No18
Yes32
Missing0
SecondarySokolow Index: FAS 2

Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Millimeter
Sokolow Index: FAS 2
MillimeterAll Participants
Sokolow Index: FAS 219.1 ± 8.8
SecondarySokolow Index: FAS 3

Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Millimeter
Sokolow Index: FAS 3
MillimeterAll Participants
Sokolow Index: FAS 318.7 ± 8.6
SecondarySokolow Index: FAS 3.1

Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Millimeter
Sokolow Index: FAS 3.1
MillimeterAll Participants
Sokolow Index: FAS 3.119.8 ± 8.7
SecondarySokolow Index: FAS 3.2

Sokolow index is calculated as sum of the amplitude of the S wave in in right precordial lead V1 and the amplitude of the highest R wave in left precordial leads V5 or V6. If the result is greater than 35 mm, it is suggestive of left ventricular hypertrophy.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Millimeter
Sokolow Index: FAS 3.2
MillimeterAll Participants
Sokolow Index: FAS 3.216.5 ± 8.4
SecondaryLeft Ventricular Ejection Fraction (LVEF): FAS 2

LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Percentage of blood volume
Left Ventricular Ejection Fraction (LVEF): FAS 2
Percentage of blood volumeAll Participants
Left Ventricular Ejection Fraction (LVEF): FAS 255.0 ± 11.4
SecondaryLeft Ventricular Ejection Fraction (LVEF): FAS 3

LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Percentage of blood volume
Left Ventricular Ejection Fraction (LVEF): FAS 3
Percentage of blood volumeAll Participants
Left Ventricular Ejection Fraction (LVEF): FAS 355.2 ± 11.2
SecondaryLeft Ventricular Ejection Fraction (LVEF): FAS 3.1

LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Percentage of blood volume
Left Ventricular Ejection Fraction (LVEF): FAS 3.1
Percentage of blood volumeAll Participants
Left Ventricular Ejection Fraction (LVEF): FAS 3.155.7 ± 11.2
SecondaryLeft Ventricular Ejection Fraction (LVEF): FAS 3.2

LVEF was defined as the central measure of left ventricular systolic function. LVEF was the fraction of stroke volume (volume ejected in systole) in relation to the volume of the blood in the ventricle at the end of diastole volume (EDV). LVEF was presented in percentage.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Percentage of blood volume
Left Ventricular Ejection Fraction (LVEF): FAS 3.2
Percentage of blood volumeAll Participants
Left Ventricular Ejection Fraction (LVEF): FAS 3.253.9 ± 11.4
SecondaryNumber of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 2

LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 2
ParticipantsAll Participants
No215
Yes26
SecondaryNumber of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 3

LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 3
ParticipantsAll Participants
No183
Yes22
SecondaryNumber of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 3.1

LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 3.1
ParticipantsAll Participants
No119
Yes17
SecondaryNumber of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 3.2

LVOT is defined as limitation of blood flow out of the left ventricle. The level of obstruction can be valvular, sub-valvular, or supravalvular. In this outcome measure participants were categorized as Yes or No on the basis of presence or absence of LVOT.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants Assessed for Left Ventricular Outflow Tract Obstruction (LVOT): FAS 3.2
ParticipantsAll Participants
No51
Yes5
SecondaryNumber of Participants Categorized According to Perseverance of Strain Apical: FAS 2

Participants were classified according to strain apical preserved as 'No' and 'Yes'.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants Categorized According to Perseverance of Strain Apical: FAS 2
ParticipantsAll Participants
No28
Yes62
SecondaryNumber of Participants Categorized According to Perseverance of Strain Apical: FAS 3

Participants were classified according to strain apical preserved as 'No' and 'Yes'.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants Categorized According to Perseverance of Strain Apical: FAS 3
ParticipantsAll Participants
No26
Yes60
SecondaryNumber of Participants Categorized According to Perseverance of Strain Apical: FAS 3.1

Participants were classified according to strain apical preserved as 'No' and 'Yes'.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants Categorized According to Perseverance of Strain Apical: FAS 3.1
ParticipantsAll Participants
No16
Yes46
SecondaryNumber of Participants Categorized According to Perseverance of Strain Apical: FAS 3.2

Participants were classified according to strain apical preserved as 'No' and 'Yes'.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants Categorized According to Perseverance of Strain Apical: FAS 3.2
ParticipantsAll Participants
No8
Yes12
SecondaryLV End Diastolic Diameter: FAS 2

Left ventricular end-diastolic diameter (LVEDD) reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Millimeter
LV End Diastolic Diameter: FAS 2
MillimeterAll Participants
LV End Diastolic Diameter: FAS 243.3 ± 7.9
SecondaryLV End Diastolic Diameter: FAS 3

LVEDD reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Millimeter
LV End Diastolic Diameter: FAS 3
MillimeterAll Participants
LV End Diastolic Diameter: FAS 343.2 ± 7.9
SecondaryLV End Diastolic Diameter: FAS 3.1

LVEDD reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Millimeter
LV End Diastolic Diameter: FAS 3.1
MillimeterAll Participants
LV End Diastolic Diameter: FAS 3.143.2 ± 7.5
SecondaryLV End Diastolic Diameter: FAS 3.2

LVEDD reflects the size of cardiac as well as left ventricular function. It was associated with progressive left ventricular insufficiency.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Millimeter
LV End Diastolic Diameter: FAS 3.2
MillimeterAll Participants
LV End Diastolic Diameter: FAS 3.244.4 ± 6.8
SecondaryMaximum Wall Thickness: FAS 2
Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Millimeter
Maximum Wall Thickness: FAS 2
MillimeterAll Participants
Maximum Wall Thickness: FAS 217.4 ± 2.5
SecondaryMaximum Wall Thickness: FAS 3
Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Millimeter
Maximum Wall Thickness: FAS 3
MillimeterAll Participants
Maximum Wall Thickness: FAS 317.5 ± 2.4
SecondaryMaximum Wall Thickness: FAS 3.1
Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Millimeter
Maximum Wall Thickness: FAS 3.1
MillimeterAll Participants
Maximum Wall Thickness: FAS 3.117.9 ± 2.5
SecondaryMaximum Wall Thickness: FAS 3.2
Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Millimeter
Maximum Wall Thickness: FAS 3.2
MillimeterAll Participants
Maximum Wall Thickness: FAS 3.216.9 ± 2.2
SecondaryNumber of Participants According to Type of Hypertrophic Pattern: FAS 2

Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants According to Type of Hypertrophic Pattern: FAS 2
ParticipantsAll Participants
Apical6
Concentric179
Asymmetric47
Mix8
SecondaryNumber of Participants According to Type of Hypertrophic Pattern: FAS 3

Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants According to Type of Hypertrophic Pattern: FAS 3
ParticipantsAll Participants
Apical4
Concentric159
Asymmetric37
Mix4
SecondaryNumber of Participants According to Type of Hypertrophic Pattern: FAS 3.1

Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants According to Type of Hypertrophic Pattern: FAS 3.1
ParticipantsAll Participants
Apical1
Concentric105
Asymmetric27
Mix2
SecondaryNumber of Participants According to Type of Hypertrophic Pattern: FAS 3.2

Participants were classified according to hypertrophic pattern as apical, concentric, asymmetric and mix.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Count of participants · Participants
Number of Participants According to Type of Hypertrophic Pattern: FAS 3.2
ParticipantsAll Participants
Apical2
Concentric46
Asymmetric7
Mix1
SecondaryLV Mass Index (LVMI): FAS 2

Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Grams per meter square
LV Mass Index (LVMI): FAS 2
Grams per meter squareAll Participants
LV Mass Index (LVMI): FAS 2172.7 ± 64.0
SecondaryLV Mass Index (LVMI): FAS 3

Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Grams per meter square
LV Mass Index (LVMI): FAS 3
Grams per meter squareAll Participants
LV Mass Index (LVMI): FAS 3177.0 ± 53.2
SecondaryLV Mass Index (LVMI): FAS 3.1

Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Grams per meter square
LV Mass Index (LVMI): FAS 3.1
Grams per meter squareAll Participants
LV Mass Index (LVMI): FAS 3.1177.0 ± 48.7
SecondaryLV Mass Index (LVMI): FAS 3.2

Left ventricular mass (LVM) is the weight of the left ventricle, typically estimated using echocardiography, and is thought to represent the cumulative effect of blood pressure on the heart. Closely related to body size, greater in men than in women, and increases with age. LVMI = LVM (left ventricular mass)/body surface area.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Grams per meter square
LV Mass Index (LVMI): FAS 3.2
Grams per meter squareAll Participants
LV Mass Index (LVMI): FAS 3.2185.5 ± 62.0
SecondaryAortic Valvular Stenosis - Aortic Valve Area: FAS 2

Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Centimeter square
Aortic Valvular Stenosis - Aortic Valve Area: FAS 2
Centimeter squareAll Participants
Aortic Valvular Stenosis - Aortic Valve Area: FAS 22.3 ± 0.8
SecondaryAortic Valvular Stenosis - Aortic Valve Area: FAS 3

Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Centimeter square
Aortic Valvular Stenosis - Aortic Valve Area: FAS 3
Centimeter squareAll Participants
Aortic Valvular Stenosis - Aortic Valve Area: FAS 32.2 ± 0.7
SecondaryAortic Valvular Stenosis - Aortic Valve Area: FAS 3.1

Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Centimeter square
Aortic Valvular Stenosis - Aortic Valve Area: FAS 3.1
Centimeter squareAll Participants
Aortic Valvular Stenosis - Aortic Valve Area: FAS 3.12.3 ± 0.7
SecondaryAortic Valvular Stenosis - Aortic Valve Area: FAS 3.2

Aortic valve stenosis is a type of heart valve disease (valvular heart disease). The valve between the lower left heart chamber and the body's main artery (aorta) is narrowed and doesn't open fully. This reduces or blocks blood flow from the heart to the aorta and to the rest of the body. Parameters needed to classify the aortic valve stenosis: peak transvalvular velocity, mean pressure gradient and aortic valve area. Here, aortic valve area is reported in this outcome measure.

Time frame:
During collection and observation duration from 09-Jul-2018 to 08-Jun-2022 (approximately 3.11 years)
Reported as:
Mean · Centimeter square
Aortic Valvular Stenosis - Aortic Valve Area: FAS 3.2
Centimeter squareAll Participants
Aortic Valvular Stenosis - Aortic Valve Area: FAS 3.22.0 ± 0.7

Adverse events

Collected over Not applicable as adverse events were not planned to be collected during the study. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants———

Baseline characteristics

Full Analysis Set 1 (FAS1) included all participants who met eligibility criteria and with a radionuclide bone scintigraphy and/or SPECT performed with 99mTechnetium-3,3-diphosphono-1,2-propanodi-carboxylic acid (99mTc-DPD) or 99mTechnetium-pyrophosphate (99mTc-PYP) or 99mTechnetium-hydroxymethylene diphosphonate (99mTc-HMDP).

Age, Continuous
Age, Continuous(Years)All Participants
Mean72.3 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female233
Male533
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
Caucasian665
Caucasian & Portuguese (or Portuguese parents)47
African21
Asian27
Other6
08

Study locations

18 sites
  • The Prince Charles Hospital
    Chermside, 4102, Australia
  • The Alfred Department of Cardiology
    Melbourne, Australia
  • Medizinische Universität Innsbruck - Universitätsklinik für Innere Medizin III, Kardiologie
    Innsbruck, A-6020, Austria
  • Centre Hospitalier Universitaire de Caen
    Caen, Cedex 14033, France
  • Hopital Henri Mondor, Service de Pharmacologie Clinique
    Creteil, 94000, France
  • CHU de Nantes
    Nantes cedex 1, 44093, France
  • CHU de Toulouse
    Toulouse, 31100, France
  • Divisione di Cardiologia
    Bologna, 40128, Italy
  • Careggi Hospital
    Florence, 50134, Italy
  • Centro Hospitalar e Universitario de Coimbra
    Coimbra, 3000-075, Portugal
  • Centro Hospitalar de Lisboa Central, E.P.E.
    Lisboa, 1150-199, Portugal
  • Fundeni Clinical Institute
    Bucharest, 022328, Romania
  • Inherited Cardiovascular Diseases - Cardiology Institute
    Bucharest, 030171, Romania
  • East Slovak Institute of Cardiovascular Diseases
    Kosice, 4011, Slovakia
  • University Medical Centre Ljubljana - Department of Cardiology
    Ljubljana, 1000, Slovenia
  • Cardiomyopathy Unit, Department of Cardiology
    Majadahonda, Madrid 28222, Spain
  • Hospital Universitario A Coruna
    A Coruna, 15006, Spain
  • The Heart Hospital - University College London Hospitals Nhs Foundation Trust
    London, W1G 8PH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Jun 2022, 46 months.

Results were first posted in Feb 2024, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2019
First posted
Feb 15, 2019
StartActual
Jul 9, 2018
Primary completionActual
Jun 8, 2022
CompletionActual
Jun 8, 2022
Results first posted
Feb 12, 2024
Last update
Feb 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03842163
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 15, 2019
Start date
Jul 9, 2018
Primary completion
Jun 8, 2022
Completion
Jun 8, 2022
Results posted
Feb 12, 2024
Last update
Feb 12, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion